Vertex Pharmaceuticals Inc. (VRTX) News

Vertex Pharmaceuticals Inc. (VRTX): $456.95

6.15 (+1.36%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

B

Add VRTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#8 of 360

in industry

Filter VRTX News Items

VRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VRTX News Highlights

  • VRTX's 30 day story count now stands at 23.
  • Over the past 25 days, the trend for VRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • AMP, LI and GENE are the most mentioned tickers in articles about VRTX.

Latest VRTX News From Around the Web

Below are the latest news stories about VERTEX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

With a new medicine on the market and plenty of money, Vertex is in great shape.

Yahoo | December 27, 2023

3 Monster Stocks to Buy Without Any Hesitation

These are easy choices for investors seeking market-beating long-term gains.

Yahoo | December 27, 2023

Should You Invest in Bluebird Bio Right Now?

After two December share price crashes, there's no evident cure for Bluebird Bio's ills.

Yahoo | December 26, 2023

3 Top Stocks to Buy Hand Over Fist Before the End of 2023

These are ideal stocks to buy sooner rather than later.

Yahoo | December 25, 2023

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals

Editas isn't out of the woods yet, but it's better off than before.

Yahoo | December 23, 2023

5 Top Stocks to Buy With Your End-of-the-Year Bonus

Your bonus could become the gift that keeps on giving.

Yahoo | December 23, 2023

Could CRISPR Therapeutics Stock Help You Become a Millionaire?

There are plenty of reasons to be optimistic about CRISPR's future.

Yahoo | December 22, 2023

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Yahoo | December 22, 2023

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Yahoo | December 22, 2023

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’

It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."

TradeSmith Research Staff on InvestorPlace | December 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!